Novartis CEO Justifies Decision To Delay Telling FDA About Manipulated Data For $2.1M Gene Therapy Drug
Novartis CEO Vas Narasimhan said the company "thoroughly, aggressively" investigated whether the issue would effect patient safety. The FDA, after publicly rebuking the company, came to a similar conclusion that patients aren't at risk because of the lapse in judgment. Other pharmaceutical industry news looks at Gilead's pricey HIV drug, cell therapies, the cost of a snakebite, and more.